Evidence map›Paper›PMID 30027033›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2018

Engineering Whole Mammalian Cells for Target-Cell-Specific Invasion/Fusion.

Ryosuke Kojima, Martin Fussenegger

Open access · goldAbstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Visualizing cell-cell communication using synthetic notch activated MRI.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  2. The evolution of synthetic receptor systems.Nature chemical biology · 2022
    Review
  3. Article
  4. Review
  5. After-Death Functions of Cell Death.The Yale journal of biology and medicine · 2019
    Review
  6. Engineering Whole Mammalian Cells for Target-Cell-Specific Invasion/Fusion.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Ryosuke KojimaDepartment of Biosystems Science and Engineering (D-BSSE) ETH Zurich Mattenstrasse 26 4058 Basel Switzerland.
Martin FusseneggerDepartment of Biosystems Science and Engineering (D-BSSE) ETH Zurich Mattenstrasse 26 4058 Basel Switzerland.ORCID 0000-0001-8545-667X
ETH Zurich · CHUniversity of Basel · CH

Funding

European Research Council 321381
6 · The paper itself

Abstract

Live mammalian cells are equipped with a synthetic cell invasion system that enables their target-specific insertion into other live mammalian cells. By conjugating RhoA activator to a transmembrane protein that is segregated from cell-cell interface when specific cell contact occurs, polarization of RhoA activity is synthetically induced inside the cells in response to specific cell contact. This polarization is a sufficient condition for invader cells to selectively penetrate cells expressing a target antigen. Further, when an acid-responsive fusogenic protein is expressed on invader cells, invader/receiver cell fusion occurs after invasion, and the invader's intracellular contents are released into the recipient's cytosol. It is shown that this system can be used for specific cell ablation. This synthetic-biology-inspired cell invasion/fusion system might open the door to using whole mammalian cells for cargo delivery purposes or for ablation of a specific cell type.

Indexed as

biotechnologycell contactscell fusioncell invasionsynthetic biology

Identifiers

PMID30027033
PMCPMC6051388
OpenAlexW2800068905

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.